RheumNow

RheumNow

Rheumnow.com serves as a dedicated news platform focused on Rheumatology. Crafted by specialists in the field, it caters to Rheumatologists and professionals in related areas. The site offers daily updates, and you can also receive the latest news directly in your inbox by subscribing to our newsletter.

Trade/B2B
English
Online/Digital

Outlet metrics

Domain Authority
35
Ranking

Global

#826406

India

#137479

Health/Health

#1328

Traffic sources
Monthly visitors

Articles

  • 5 days ago | rheumnow.com | Jack Cush

    An overview of denosumab use in osteoporosis (OP)  by Bauer and Ensrud was published in JAMA. Denosumab plays an important role in OP guidelines, often secondary to antiresorptive agents such as bisphosphonates (usual first-line therapy).  Yet, denosumab is recommended as it is more convenient, has fewer gastrointestinal adverse effects, and its use is increasing while bisphosphonate use remains constant.  3-year persistence with denosumab and bisphosphonates are similar (approximately 50%).

  • 1 week ago | rheumnow.com | Jack Cush

    Dr. Jack Cush reviews the book/movie, "Moneyball" and a suggests moneyball strategy is needed to find next level responses for our patients.

  • 1 week ago | rheumnow.com | Jack Cush

    A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic  manifestations improve with BEL and standard care. A post hoc study included pooled data from belimumab trials (Be-SLE; BLISS-52, BLISS-76, BLISS-SC, and EMBRACE) conducted between 2007 and 2018. Adults with active SLE were treated with either BEL (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo, plus standard therapy (ST).

  • 1 week ago | rheumnow.com | Jack Cush

    The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. Overall, the goals of SLE management are to achieve remission or a low level disease activity, reduce morbidity and mortality, and minimize treatment-related adverse events.

  • 1 week ago | rheumnow.com | Jack Cush

    A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to reduced the risk of adverse pregnancy outcomes (APOs) in high-risk patients with APS.

RheumNow journalists

Contact details

Address

123 Example Street

City, Country 12345

Phone

+1 (555) 123-4567

Email Patterns

Socials

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Traffic locations